A
Aimery de Gramont
Researcher at French Institute of Health and Medical Research
Publications - 228
Citations - 20131
Aimery de Gramont is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 51, co-authored 211 publications receiving 18262 citations. Previous affiliations of Aimery de Gramont include University of Paris.
Papers
More filters
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand,Thierry André,Emmanuel Achille,Gérard Lledo,Michel Flesh,Dominique Méry-Mignard,E. Quinaux,C. Couteau,Marc Buyse,Gérard Ganem,B. Landi,Philippe Colin,Christophe Louvet,Aimery de Gramont +13 more
TL;DR: Both sequences achieved a prolonged survival and similar efficacy in metastatic colorectal cancer and the toxicity profiles were different.
Journal ArticleDOI
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry André,Corrado Boni,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Andrea Bonetti,Philip Clingan,John Bridgewater,Fernanado Rivera,Aimery de Gramont +10 more
TL;DR: Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease.
Journal ArticleDOI
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand,Andrés Cervantes,Arie Figer,Gérard Lledo,M. Flesch,Marc Buyse,Laurent Mineur,Elisabeth Carola,Pierre-Luc Etienne,Fernando Rivera,Isabel Chirivella,N. Perez-Staub,Christophe Louvet,Thierry André,Isabelle Tabah-Fisch,Aimery de Gramont +15 more
TL;DR: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen, and further study is needed to fully evaluate oxali Platin reintroduction.
Journal ArticleDOI
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel J. Sargent,Harry S. Wieand,Daniel G. Haller,Richard Gray,Jacqueline Benedetti,Marc Buyse,Roberto Labianca,Jean Francois Seitz,Christopher J. O'Callaghan,Guido Francini,Axel Grothey,Michael J. O'Connell,Paul J. Catalano,Charles D. Blanke,David J. Kerr,Erin M. Green,Norman Wolmark,Thierry André,Richard M. Goldberg,Aimery de Gramont +19 more
TL;DR: It is suggested that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.